News and publications
Invoke Bio's NEMo: Evolutionary Machine Learning for Neoantigen Immunogenicity Prediction
NEMo uses evolutionary machine learning trained on 25,000+ immune checkpoint blockade mutations, treating immune-driven neoantigen elimination as a training signal. Validated across the TESLA benchmark and two cancer vaccine clinical trials.
More news

Open Data
Designing a Personalized Cancer Vaccine from Sid Sijbrandij's Data
Designing a Personalized Cancer Vaccine from Sid Sijbrandij's Data

QB3
Teaching Cancer Vaccines What to Target: Invoke Bio Turns to AI
Teaching Cancer Vaccines What to Target: Invoke Bio Turns to AI

bioRxiv Preprint
Learning What Cancer Reveals: Introducing NEMo
Learning What Cancer Reveals: Introducing NEMo

QB3
Invoke Bio Wins $100,000 QB3 Mentoring Program Award
Invoke Bio Wins $100,000 QB3 Mentoring Program Award
See all
news
